Fluphenazine decanoate in acute and maintenance therapy of schizophrenia

Alfredo Carlo Altamura, Massimo C. Mauri, Grazia Guercetti, Carlo L. Cazzullo

Research output: Contribution to journalArticle


1. 1. The knowledge of the pharmacokinetic profile of fluphenazine decanoate (FPZ-D) suggested it was suitable for treatment of schizophrenic patients not just during the maintenance phase of the disease but also during acute relapses. 2. 2. 27 acute schizophrenic in-patients (diagnosed according to the DSK III) were treated with FPZ-D, 25 mg i.m. with repeated administrations (after 2, 4, 30 days). 3. 3. FPZ-D proved effective in all cases, already after the second day and particularly on Brief Psychiatric Rating Scale items such as delusion, hallucinations, hostility. 4. 4. Extrapyramidal side-effects, appeared in about 40% of the patients. 5. 5. The use of the drug both in the acute phase and maintenance schizophrenia therapy is envisaged, overcoming the problems deriving from the rejection by patients of any therapeutic tool and consequently the therapeutic "milieu".

Original languageEnglish
Pages (from-to)613-623
Number of pages11
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Issue number5
Publication statusPublished - 1987


  • acute schizophrenia
  • fluphenazine decanoate
  • maintenance therapy

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Fingerprint Dive into the research topics of 'Fluphenazine decanoate in acute and maintenance therapy of schizophrenia'. Together they form a unique fingerprint.

  • Cite this